Regeneron Pharmaceuticals, Inc.
REGN
Positions held
Your positionsREGN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Regeneron Pharmaceuticals has a strong competitive advantage due to its innovative drug pipeline and established market presence, particularly in the treatment of eye diseases and cancer.
- In Q2 2026, Regeneron reported a 19% increase in revenue compared to the previous quarter, reaching $4.3 billion.
- The company's gross margin improved to 86.6% in Q2 2026, up from 81.4% in Q1 2026.
- Regeneron's earnings growth has been declining, which raises concerns about its long-term profitability and market sustainability.
- In Q1 2026, net income was $727.2 million, a decrease from $844.6 million in Q4 2025.
- The company's trailing P/E ratio is 18.27, indicating that the stock may be overvalued compared to its earnings growth.
Fundamentals
| Market cap | $76.14B | Enterprise value | $68.56B | Trailing P/E | 18.29 | Forward P/E | 11.99 |
| PEG | 1.27 | Price / book | 2.34 | Beta | 0.15 | Dividend yield | 0.51% |
| Revenue growth | 16.7% | Earnings growth | -4.5% | Gross margin | 44.5% | Operating margin | 33.1% |
| Profit margin | 27.9% | ROE | 14.0% | ROA | 6.5% | Debt / equity | 0.09 |
| Current ratio | 3.34 | Free cash flow | $3.07B | Analyst recommendation | buy | Mean target | $859.04 |
| 52w high | $859.34 | 52w low | $541.00 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $4.3B | $3.6B | $3.9B | $3.8B | $3.7B |
| Op margin | 33.1% | 20.7% | 23.1% | 29.6% | 29.4% |
| Net income | $1.3B | $727M | $845M | $1.5B | $1.4B |
| Gross margin | 86.6% | 81.4% | 84.9% | 86.1% | 85.6% |
| Gross profit | $3.7B | $2.9B | $3.3B | $3.2B | $3.1B |
| Operating income | $1.4B | $745M | $899M | $1.1B | $1.1B |
- Revenue +19% vs prior quarter ($4.3B vs $3.6B).
- Gross margin 86.6% (was 81.4% prior quarter).
- Operating margin expanded to 33.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $14.3B | $14.2B | $13.1B | $12.2B | — |
| Op margin | 25.8% | 28.1% | 30.9% | 38.9% | — |
| Net income | $4.5B | $4.4B | $4.0B | $4.3B | — |
| Gross margin | 85.4% | 86.1% | 86.2% | 87.2% | — |
| Gross profit | $12.2B | $12.2B | $11.3B | $10.6B | — |
| Operating income | $3.7B | $4.0B | $4.0B | $4.7B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Is Vertex Stock Worth More Than Its Competitors?
2026-10-09 · What Is Going On With Regeneron Stock?
2026-10-08 · Bayer Seeks Kerendia Label Expansion in Non-Diabetic CKD
2026-10-08 · RBC Raises Price Target on Regeneron Pharmaceuticals to $810 From $737, Keeps Sector Perform Rating
2026-10-08 · Is Biohaven (BHVN) Quietly Recasting Its Oncology Strategy Through Deeper Ties With Regeneron?
2026-10-07 · Morgan Stanley Adjusts Price Target on Regeneron Pharmaceuticals to $779 From $758
2026-10-06 · Expanded Sanofi Alliance And New Pipeline Data Could Be A Game Changer For Regeneron (REGN)
2026-10-06 · Health Care Roundup: Market Talk
2026-10-06 · Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
2026-10-06 · JPMorgan Adjusts PT on Regeneron Pharmaceuticals to $950 From $900, Keeps Overweight Rating
2026-10-03 · Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets
Price (daily)
Full chart · RSI · MACD · patterns